Please login to the form below

Not currently logged in
Email:
Password:

anaesthetics

This page shows the latest anaesthetics news and features for those working in and with pharma, biotech and healthcare.

Sandoz expands into Japan with €400m Aspen deal

Sandoz expands into Japan with €400m Aspen deal

Aspen’s portfolio consists of approximately 20 off-patent medicines, including anaesthetics like Xylocaine and speciality brands such as immune suppressing drug Imuran for multiple sclerosis patients.

Latest news

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    200+. Janssen / J&J (US). Piramal (IN). Asset acquisition. 5 injectable pain / anaesthetic products.

  • Deal Watch September 2016 Deal Watch September 2016

    500. GSK / Aspen. Asset acquisition. Sale of anaesthetic drugs [Ultiva, Nimbex, Tracrium, Mivacron and Anectinein – excludes US/CA rights].

  • Deal Watch June 2016 Deal Watch June 2016

    Meanwhile AstraZeneca has out-licensed ex-US rights to a portfolio of seven anaesthetics to Aspen. ... Paying $520m upfront Aspen gains access to a series of local anaesthetics including Marcaine (bupivacaine) and Xylocaine (lidocaine/ lignocaine), and

  • Pharma deals in June 2015 Pharma deals in June 2015

    Neosaxitoxin, novel anaesthetic for local anaesthesia and post-op pain management. Collaboration, licence.

  • Pharma deals during March 2014 Pharma deals during March 2014

    Baxter's medical products business has annual sales of over $9bn and a portfolio of intravenous solutions and nutritional therapies, drug delivery systems, premixed and other injectable drugs, inhalation anaesthetics and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...
Happy Chinese New Year 2020 - The Year of The Rat
A fond farewell to The Year of the Pig...

Infographics